D-0169-2017 Class III Terminated
FDA drug recall D-0169-2017 was initiated by Hospira Inc. on Jun 29, 2016 and is designated Class III. Reason for recall: Failed Stability Specifications: The recalled lots did not meet the specification for color and pH throughout shelf life. The recall status is terminated (terminated Nov 20, 2019). Affected quantity: 287,200 2 mL ampules.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 14, 2016
- Initiation Date
- Jun 29, 2016
- Termination Date
- Nov 20, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 287,200 2 mL ampules
Product description
5% Lidocaine HCL and 7.5% Dextrose Injection, USP, 2 mL Single-dose ampule, 5 count box, Rx Only, For Spinal Anesthesia Only, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-4712-01
Reason for recall
Failed Stability Specifications: The recalled lots did not meet the specification for color and pH throughout shelf life.
Distribution pattern
US and Puerto Rico
Code information
Lot # 34-547-DK, 34-548-DK, Exp. 10/16, Lot # 39-372-DK, Exp. 03/17 Lot Number may be followed by numbers from 01 to 99
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0169-2017
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Hospira Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.